MediWound (FRA:M8W) FFO


FRA:M8W MediWound Ltd FRA:M8W
56 GF Score
Price €12.60
GF Value €10.53
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound FFO?

FFO (Funds from operations) only applies to REITs.

FRA:M8W
56GF Score
MediWound Ltd FRA:M8W
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MediWound (FRA:M8W) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of €12.60 is trading 19.7% above its estimated GF Value™ of €10.53. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for FRA:M8W:

  • FFO:
  • GF Value™: €10.53 vs. price of €12.60 (19.7% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FRA:M8W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges MDWD:USA
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for FRA:M8W

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.60
Price
€10.53
GF Value